Get the Stockscreener App
1.26
1.61%
0.02
After Hours:
1.29
0.03
+2.38%
Lyra Therapeutics Inc stock is traded at $1.26, with a volume of 46,787.
It is up +1.61% in the last 24 hours and down -33.16% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$1.24
Open:
$1.25
24h Volume:
46,787
Relative Volume:
0.50
Market Cap:
$2.24M
Revenue:
$770.00K
Net Income/Loss:
$-38.84M
P/E Ratio:
-0.0887
EPS:
-14.2049
Net Cash Flow:
$-43.02M
1W Performance:
-10.00%
1M Performance:
-33.16%
6M Performance:
-82.10%
1Y Performance:
-86.15%
1-Day Range:
$1.225
$1.35
1-Week Range:
$0.9062
$1.46
52-Week Range:
$0.9062
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
1.26 | 2.20M | 770.00K | -38.84M | -43.02M | -14.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Growth Review: Will Lyra Therapeutics Inc be affected by tariffsJuly 2025 Earnings & Technical Confirmation Trade Alerts - baoquankhu1.vn
LYRA Technical Analysis & ETF Price Forecast - Intellectia AI
Lyra Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Lyra Therapeutics receives default notice for unpaid rent as wind-down continues - Investing.com India
LYRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
LYRA Technical Analysis & Stock Price Forecast - Intellectia AI
Lyra Therapeutics receives default notice for unpaid rent as wind-down continues By Investing.com - Investing.com South Africa
LYRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lyra Therapeutics (LYRA) hit with sublease default as it winds down - Stock Titan
LYRA Should I Buy - Intellectia AI
Short Covering: What are the risks of holding Lyra Therapeutics IncWeekly Market Outlook & AI Powered Market Entry Ideas - baoquankhu1.vn
LYRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Lyra Therapeutics Inc be affected by tariffs2025 Institutional Moves & Daily Market Momentum Tracking - baoquankhu1.vn
Pullback Watch: Is Lyra Therapeutics Inc stock a good pick for beginnersJuly 2025 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Stock Report: What is Lyra Therapeutics Incs P E ratio telling usWeekly Trade Analysis & Verified Short-Term Trading Plans - baoquankhu1.vn
Quarterly Risk: Will Lyra Therapeutics Inc be affected by tariffs2025 Analyst Calls & Risk Controlled Daily Plans - baoquankhu1.vn
Can Lyra Therapeutics Inc. outperform under higher oil pricesQuarterly Portfolio Report & Safe Capital Investment Plans - mfd.ru
What are the analyst revisions for Lyra Therapeutics Inc.Is BBAR stock a good investment in YEARTrade Entry Report & Daily Profit Focused Stock Screening - mfd.ru
Is Lyra Therapeutics Inc. stock vulnerable to regulatory risksWeekly Trading Summary & Consistent Growth Stock Picks - mfd.ru
Analyst Upgrade: How much upside does Lyra Therapeutics Inc haveJuly 2025 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Lyra Therapeutics Faces Nasdaq Delisting Battle After Clinical Setback - AD HOC NEWS
Lyra Therapeutics Faces Nasdaq Delisting After Becoming Shell - The Globe and Mail
Lyra Therapeutics (LYRA) Faces Nasdaq Delisting - GuruFocus
Lyra Therapeutics Faces Nasdaq Delisting Over Shell Company Concerns, Capital Shortfall - marketscreener.com
Lyra Therapeutics Received Notice of Delisting - TradingView
Nasdaq plans to delist Lyra Therapeutics (LYRA) after shell status finding - Stock Titan
What is the dividend yield of Lyra Therapeutics IncMarket Risk Analysis & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Sectors: Can Lyra Therapeutics Inc grow without external funding2025 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
Why hedge funds are buying Lyra Therapeutics Inc. stockJuly 2025 Drop Watch & Safe Capital Growth Trade Ideas - mfd.ru
What is the dividend yield of Lyra Therapeutics Inc.July 2025 EndofMonth & Verified Swing Trading Watchlist - mfd.ru
Should I buy Lyra Therapeutics Inc. stock nowWeekly Profit Summary & Weekly Setup with High ROI Potential - mfd.ru
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Downgrade Watch: Will Lyra Therapeutics Inc benefit from green energy policies2025 Retail Activity & Consistent Income Trade Recommendations - baoquankhu1.vn
How Lyra Therapeutics Inc. stock reacts to Fed rate cutsFederal Reserve Announcements & Fast Growing Portfolio Trading - bollywoodhelpline.com
How cyclical is Lyra Therapeutics Inc.’s revenue streamPortfolio Performance Summary & Accurate Intraday Trading Signals - Bollywood Helpline
Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch - RTTNews
Aug Spikes: Is Lyra Therapeutics Inc stock a good pick for beginnersJuly 2025 Recap & Consistent Return Strategy Ideas - baoquankhu1.vn
Bearish Setup: Will Cheniere Energy Inc stock hit new highs in YEARWeekly Loss Report & Safe Entry Point Identification - baoquankhu1.vn
Layoff Tracker: Lyra Shutters, EMD Serono Downsizes - BioSpace
How much upside does Lyra Therapeutics Inc. have2025 Valuation Update & Weekly Sector Rotation Insights - Bollywood Helpline
Take Profit: Is CRTO forming bullish engulfing patternsWeekly Trade Report & Verified Technical Signals - baoquankhu1.vn
EV Market: Will Lyra Therapeutics Inc stock maintain momentum in 2025Analyst Downgrade & Weekly Return Optimization Plans - Bộ Nội Vụ
Lyra Therapeutics suspends further development of LYR-210 - Yahoo Finance
Lyra Therapeutics halts development of lead CRS treatment By Investing.com - Investing.com Nigeria
Mass. biotech company lays off entire workforce as cash dwindles - nbcboston.com
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Watertown biotech suspends drug development and eliminates workforce as cash dwindles - The Business Journals
Lyra Therapeutics, Inc. Announces Termination of Jason Cavalier as Chief Financial Officer - marketscreener.com
LYRA Plunges 55% After Company Halts Lead Program And Begins Strategic Review - Nasdaq
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):